Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Ritz

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
The Journal of Infectious Diseases|August 31, 2023
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 TrialCarlee B Moser, Kara W Chew, Justin Ritz, et al.
The Lancet. Digital Health|September 19, 2019
Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trialRobert Gross, Justin Ritz, Michael D Hughes, et al.
Annals of Internal Medicine|November 24, 2015
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled TrialKaren T Tashima, Laura M Smeaton, Carl J Fichtenbaum, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Contemporary Clinical Trials|March 27, 2025
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trialMark J Giganti, Kara W Chew, Carlee Moser, et al.
Scientific Reports|March 20, 2026
Association of long COVID with health-related quality-of-life outcomesMalini M Gandhi, Carlee Moser, Judith S Currier, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
Open Forum Infectious Diseases|October 27, 2018
Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ARTSharon A Riddler, Lu Zheng, Christine M Durand, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
The Journal of Infectious Diseases|August 31, 2023
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 TrialCarlee B Moser, Kara W Chew, Justin Ritz, et al.
The Lancet. Digital Health|September 19, 2019
Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trialRobert Gross, Justin Ritz, Michael D Hughes, et al.
Annals of Internal Medicine|November 24, 2015
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled TrialKaren T Tashima, Laura M Smeaton, Carl J Fichtenbaum, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Contemporary Clinical Trials|March 27, 2025
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trialMark J Giganti, Kara W Chew, Carlee Moser, et al.
Scientific Reports|March 20, 2026
Association of long COVID with health-related quality-of-life outcomesMalini M Gandhi, Carlee Moser, Judith S Currier, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
Open Forum Infectious Diseases|October 27, 2018
Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ARTSharon A Riddler, Lu Zheng, Christine M Durand, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Pageof 6